Effect of secretory DKK3 on circulating CD56bright natural killer cells in patients with liver cancer

被引：0
|
作者：
Liu, Da-Hua [1 ]
Wen, Gui-Min [2 ]
Song, Chang-Liang [3 ]
Xia, Pu [1 ,4 ]
机构：
[1] Jinzhou Med Univ, Biol Anthropol Inst, Coll Basic Med Sci, Jinzhou, Liaoning, Peoples R China
[2] Jinzhou Med Univ, Coll Nursing, Dept Community Nursing, Jinzhou, Liaoning, Peoples R China
[3] Ctr Hosp Handan, Dept Radiotherapy, Handan, Hebei, Peoples R China
[4] Jinzhou Med Univ, Biol Anthropol Inst, Jinzhou 121000, Liaoning, Peoples R China
来源：
INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS | 2023年 / 38卷 / 02期
基金：
中国国家自然科学基金;
关键词：
Liver cancer; DKK3; NK cells; differentiation; cytotoxicity; NK CELLS; METHYLATION; EXPRESSION; MECHANISM; ALPHA;
D O I：
10.1177/03936155231169796
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Background Liver cancer seriously threatens human health. Natural killer (NK) cells are an important part of the innate immune system and have strong anti-tumor ability. Immunotherapy based on NK cells has become a hot topic in the treatment of liver cancer. Methods In this study, we checked the serum DKK3 (sDKK3) and circulating CD56(bright) NK cells using ELISA and flow cytometry, respectively, in the blood of liver cancer patients. The effect on recombinant human DKK3 (rhDKK3) on CD56(bright) NK cells was analyzed in vitro. Results We found low levels of sDKK3 in liver cancer patients and a negative correlation between sDKK3 and circulating CD56(bright) NK cells. In addition, we found that DKK3 induced the differentiation and improved the cytotoxicity of CD56(bright) NK cells for the first time. It could be used as an agonist for NK cell-based immunotherapy. Conclusions Improving the clinical efficacy of NK cells through DKK3 will become a new strategy for cancer immunotherapy.
引用
收藏
页码：99 / 104
页数：6
相关论文
共 50 条
  • [31] Perturbation of the natural killer cell compartment during primary human immunodeficiency virus 1 infection primarily involving the CD56bright subset
    Mantegani, Paola
    Tambussi, Giuseppe
    Galli, Laura
    Din, Chiara Tassan
    Lazzarin, Adriano
    Fortis, Claudio
    IMMUNOLOGY, 2010, 129 (02) : 220 - 233
  • [32] Combined Serum DKK3 and Circulating CDI33 Cells as Prognostic Cancer Patients
    Nie, Xiao-Cui
    He, Fang
    Lan, Chong
    Niu, Ju-Min
    Xia, Pu
    ONCOTARGETS AND THERAPY, 2021, 14 : 427 - 434
  • [33] Expansion of cytotoxic CD56bright natural killer cells during T-cell deficiency after allogeneic hematopoietic stem cell transplantation
    Lugthart, Gertjan
    Goedhart, Marieke
    van Leeuwen, Merle M.
    Melsen, Janine E.
    Zijde, Cornelia M. Jol-van der
    Vervat, Carly
    van Ostaijen-ten Dam, Monique M.
    Jansen-Hoogendijk, Anja M.
    van Tol, Maarten J. D.
    Lankester, Arjan C.
    Schilham, Marco W.
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2017, 140 (05) : 1466 - +
  • [34] A semen-based stimulation method to analyze cytokine production by uterine CD56bright natural killer cells in women with recurrent pregnancy loss
    Taima, Ayako
    Fukui, Atsushi
    Yamaya, Ayano
    Yokota, Megumi
    Fukuhara, Rie
    Yokoyama, Yoshihito
    JOURNAL OF REPRODUCTIVE IMMUNOLOGY, 2020, 142
  • [35] An early increase of CD56bright natural killer subset as dominant effect and predictor of response to extracorporeal photopheresis for graft-versus-host disease
    Iniesta, Pastora
    Revilla, Nuria
    Chen-Liang, Tzu Hua
    Hurtado, Ana Maria
    Vicente, Vicente
    Heras, Inmaculada
    Jerez, Andres
    Luisa Lozano, Maria
    TRANSFUSION, 2018, 58 (12) : 2924 - 2932
  • [36] Imbalance between CD56+bright and CD56+dim natural killer cell subsets in the liver of patients with recurrent hepatitis C after liver transplantation
    Yamagiwa, Satoshi
    Sato, Yoshinobu
    Ichida, Takafumi
    Setsu, Toru
    Tominaga, Kentaro
    Kamimura, Hiroteru
    Tsuchiya, Atsunori
    Takamura, Masaaki
    Matsuda, Yasunobu
    Aoyagi, Yutaka
    BIOMEDICAL RESEARCH-TOKYO, 2014, 35 (03): : 177 - 184
  • [37] The small subset of CD56bright CD16- natural killer cells is selectively responsible for both cell proliferation and interferon-γ production upon interaction with dendritic cells
    Vitale, M
    Della Chiesa, M
    Carlomagno, S
    Romagnani, C
    Thiel, A
    Moretta, L
    Moretta, A
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (06) : 1715 - 1722
  • [38] Interferon-beta-1a treatment increases CD56bright natural killer cells and CD4+CD25+Foxp3 expression in subjects with multiple sclerosis
    Vandenbark, Arthur A.
    Huan, Jianya
    Agotsch, Marisa
    La Tocha, Dorian
    Goelz, Susan
    Offner, Halina
    Lanker, Stefan
    Bourdette, Dennis
    JOURNAL OF NEUROIMMUNOLOGY, 2009, 215 (1-2) : 125 - 128
  • [39] Murine CXCR3+CD27bright NK cells resemble the human CD56bright NK-cell population
    Marquardt, Nicole
    Wilk, Esther
    Pokoyski, Claudia
    Schmidt, Reinhold E.
    Jacobs, Roland
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2010, 40 (05) : 1428 - 1439
  • [40] Increased bone marrow CD56bright natural killer cells at 30 days after allogeneic stem cell transplantation associated with adverse patient outcome
    Wang, Ren Ching
    Mori, Shahram
    Zhu, Xiang
    Varela, Juan Carlos
    Dickman, Debbie
    Patel, Rushang
    Ward, David
    Goldstein, Steven C.
    Chang, Chun-Che
    BONE MARROW TRANSPLANTATION, 2019, 54 (06) : 924 - 927
12345